Supplementary Table 1 Comparison of lung cancer population-based survival.
Author
Bossard et al.
(2006)21
Type of database, year of diagnosis and patient
demographics
Database
Year
diagnosis
Eligibility
Cases
Campling et
al. (2005)12
Stage
Treatment
Database
Year
diagnosis
Eligibility
Cases
Stage
Treatment
Cartman et al.
(2002)13
Database
Cases
Stage
Treatment
Database
Year
diagnosis
Eligibility
Cases
DCO excluded (6.4%) those
managed outside region (1.5%)
Included no pathology (34%)
22,645; 67% men
No data given
11% surgery
England and Wales Cancer
Registries
1996–1999
DCO and date of death=date
diagnosis and those lost to follow
up(2.3%) excluded
107,317; 64% men, age not stated
No data given
No data given
Alberta Cancer Registry
1998
All pathology, no DCO. No medical
records excluded (17%)
611; 55% men, mean age 88 years
Stage
Surgery
21% Stage I–II, 37% Stage IV
Database
Year
diagnosis
Eligibility
Bas Rhin Cancer Registry
Cases
695; 87% men median age 63 years
Stage
Surgery
41% stage I–II , 35% Stage IV
Database
4% lost to
follow-up
Sex and age
prognostic
Overall
survival 5years
15%
Black patients
had inferior
survival to white
patients and
Veterans when
compared with
non-Veterans
No data given
1986–1994
Eligibility
Fu et al.
(2005)8
22% ‘other pathology’, death
certificate only registrations (DCO)
excluded. Men only
27,936; median age 70 years
22% Stage I–II, 43% Stage IV (9%
unknown)
Comments
Relative
survival 5years
Men 12%;
women 16%
1995–1999
Year
diagnosis
Year
diagnosis
Foegle et al.
(2005)9
Not stated
19,507; % men and median age not
stated
No data given
No data given
Pennsylvania Cancer Registry
Northern and Yorkshire Cancer
registry
Cases
Stage
Treatment
Demeter et al.
(2003)14
1987–1999
Database
Eligibility
Coleman et al.
(2004)40
French Cancer Registries (13%
population coverage)
Survival
Overall
survival 5years
4%
Relative
survival 5years
6%
Use of surgery
varied 4% to
17% by district
of residence
No change
since 1980’s.
Inferior survival
in men from
deprived areas
but not women
Overall
survival 2years
NSCLC 24%,
SCLC 10%
18% surgery
1994–1997
NSCLC only, no DCO
Relative
survival 5years
16%
Random sample
40% selected
for case review
but 10%
rejected as
charts not
available
33% surgery
SEER, USA; 23% US population
covered
Relative
survival 5-
Women had
superior survival
Year
diagnosis
1975–1999 (2 cohorts 1975–1987
and 1988–1999)
Eligibility
No pathology and DCO excluded
Cases
Stage
Gadgeel et al.
(2001)1
Surgery
26% surgery
Database
Detroit SEER Registry (99%)
Year
diagnosis
1973–1998 (two cohorts 1973–
1985, 1986–1998)
Eligibility
No pathology and DCO excluded
Cases
Stage
Surgery
Gregor et al.
(2001)2
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Jack et al.
(2003)23
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Jemal et al.
(2004)76 a
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Laskin et al.
(2004)15
Database
Year
diagnosis
Eligibility
Cases
Mennecier et
al. (2003)10
[AU: Please
228,572; 64% men, median age 66
years
18% Stage I–II , 44% Stage IV (9%
unknown)
Stage
Surgery
Database
Year
diagnosis
48,318; 66% men median age 66
years (whole series)
22% Stage I–II, 48% Stage IV (9%
unknown)
years for
1988–1999
cohort
14% men,
17% women
Relative
survival 5
years
for 1986–1998
16% white,
12% black
Whole study
period (1975-98)
Stage IV
49% black; 45%
white
Squamous cell
40% black; 33%
white
Relative
survival 5years 6%
Inferior survival
older age,
deprivation,
men, not seeing
specialist
No data given
Scotland
1995
No pathology included DCO
excluded
3,855; 61% men, median age 70
years
25% Stage I–II, 31% Stage IV (11%
unknown)
11% surgery
Thames Cancer Registry
1995–1999
No pathology cases included DCO
excluded (19%)
32,818, 63% men
35% Stage I–II, 30% Stage IV (27%
unknown)
7% surgery
Relative
survival 3years
11% (8% if
DCO included)
USA; SEER and NPCR
1995–2000
DCO and no pathology excluded
75,341 patients
16% local, 20% region 53% mets
10% unknown
Relative
survival 5years
Men 13.6%
Women 17.2%
British Columbia Cancer Registry
SCLC only, DCO excluded
614; 55% men, median age 68
years
33% limited stage
Not applicable
Bas Rhin Cancer Registry
1993–1994
Improved
survival for men
and women
since 1975–
1979
Survival 1995–
2000 localized
48%, regional
23%, mets 3%
No data given
1990 and 1995
Survival range
7–17% in
different health
authorities;
Younger
patients, women
lived longer but
no impact of
deprivation
Overall
survival 5
years
4%
Overall
survival 2years
Limited stage
8%
Extensive stage
2%
confirm this
reference is
correct]
Lebitasy et al.
(2001)16
Mahmud et al.
(2003)72
Eligibility
Cases
Stage
Surgery
Database
Republic of Ireland Cancer Registry
96% ascertainment
Year
diagnosis
1994–1998
Eligibility
Cases
Stage
Surgery
Makitaro et al.
(2002)17
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
McDavid et al.
(2003)22
Database
Year
diagnosis
Eligibility
Cases
Stage
Richardson et
al. (2000)18
Surgery
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Talback et al.
(2003) 24
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Tsukuma et
al. (2006)39
Vinod et al.
(2004)19
Vinod et al.
SCLC only, no medical records
excluded (19%)
787; 88% men median age 63 years
36% limited stage
No data given
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Database
Year
diagnosis
No pathology cases included, DCO
excluded (1%)
7,286, 66% men, median age 70
years
Not stated
12% surgery
Northern Finland Prospective
Regional audit
1990–1992
No pathology included, DCO
excluded
602; 85% men, mean age 68 years
23% Stage I–II , 41% Stage IV
20% surgery
Kentucky Cancer Registry (100%
ascertainment)
1995–1998
DCO and date of death = date
diagnosis excluded (5%)
12,477 patients; 62% men
21% Stage I–II, 41% Stage IV (12%
unknown)
22% surgery
Victoria Cancer Registry
1993
No pathology included DCO
excluded
868, 70% men, median age 69
23% localized; 37% Stage IV (30%
unknown)
23% surgery
Swedish Cancer Registry
(ascertainment >98%)
1994–1996
DCO excluded
Data not given
Data not given
Data not given
Japan Cancer Registries
1993–1996
DCO excluded
24,316; 73% men
Data not given
Data not given
New South Wales Cancer Registry
1996
9% (SCLC
only)
Cancerspecific
survival
5-years
9%
Overall
survival 5-yrs
12%
Relative
survival 3
years
19% women
and 14% men
Survival
improved from
4% 1968–1971
Patients without
private
insurance had
inferior survival
Overall
survival 5years
11%
Relative
survival 5years
17%
No improvement
in survival since
1960s
Relative
survival 5years
23%
Overall
survival 5years
Compared 3
regions – more
rural area less
(2003) 25
Hui et al.
(2005)77 a
Eligibility
Cases
Stage
Surgery
No pathology cases included, not
clear if DCO excluded
761; 50% men, median age 70
years
26% Stage I–II 37% Stage IV
7–11%
19% surgery
Yeole (2005)26
Yeole and
Kumar
(2004)78 a
Database
Year
diagnosis
Eligibility
Cases
Stage
Surgery
Mumbai Cancer Registry
1992–1994
No pathology included, DCO
excluded
1,230; 80% men
34% Stage I–II, 26% Stage IV
Relative
survival 5years 16%
radiotherapy
and
chemotherapy
but no
difference in
survival. Also no
impact of
deprivation on
stage treatment
or survival
6% lost to follow
up
Muslim patients
had reduced
hazard of death
compared with
Hindu patients
5% surgery
aReferences
76
for articles not cited in the printed text.
Jemal A et al. (2004) Annual report to the nation on the status of cancer, 1975–2001,
with a special feature regarding survival. Cancer 101: 3–27
77
Hui AC et al. (2005) Socio-economic status and patterns of care in lung cancer. Aust
N Z J Public Health 29: 372–377
78
Yeole BB and Kumar AV (2004) Population-based survival from cancers having a
poor prognosis in Mumbai (Bombay), India. Asian Pac J Cancer Prev 5: 175–182